Avalyn Pharma (NASDAQ:AVLN) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Avalyn Pharma from “Hold” to “Sell.” Despite the downgrade, analyst sentiment remains a “Moderate Buy” overall, with a consensus price target of $60 and ratings ranging from Strong Buy to Sell.
• Avalyn shares opened at $31.52, down 5.7%, with a market capitalization of approximately $1.40 billion. The company reported a quarterly loss of $0.98 per share, beating the consensus estimate of a $1.03 loss.
• Several institutional investors established new positions in Avalyn during the second quarter, including Montanova Capital, Braidwell and Bank of New York Mellon. The clinical-stage biopharmaceutical company is developing inhaled therapies for serious pulmonary diseases, led by its AP01 program for idiopathic pulmonary fibrosis.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

Several other analysts have also issued reports on the company. Evercore began coverage on Avalyn Pharma in a report on Tuesday, May 26th. They set an "outperform" rating and a $51.00 target price on the stock. Weiss Ratings started coverage on Avalyn Pharma in a research note on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Zacks Research raised shares of Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Morgan Stanley increased their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Thursday, August 13th. Finally, Guggenheim began coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $80.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $60.00.

Avalyn Pharma Stock Down 5.7%

Shares of AVLN stock opened at $31.52 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The firm has a market capitalization of $1.40 billion and a price-to-earnings ratio of -1.38. The stock has a 50-day moving average price of $33.33. Avalyn Pharma has a 12 month low of $24.15 and a 12 month high of $40.17.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.05. Sell-side analysts predict that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Braidwell LP bought a new stake in Avalyn Pharma during the 2nd quarter worth approximately $26,382,000. Montanova Capital LLC bought a new position in shares of Avalyn Pharma during the second quarter valued at $82,402,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Avalyn Pharma during the second quarter valued at $1,321,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn's lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.